Investor Relations

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta® (lefamulin), approved by the FDA in 2019 for both Oral and IV use, and CONTEPO (fosfomycin) for injection. The approval of CONTEPO has been impacted by FDA’s travel restrictions due to COVID-19. We have engaged with the FDA to determine next steps for CONTEPO. In July 2020, Nabriva Therapeutics entered into an exclusive agreement with Merck & Co. Inc., to promote and distribute SIVEXTRO (tedizolid phosphate) in the United States and certain of its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and adolescent patients for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and Fort Washington, PA.

Events & Presentations

Upcoming
More events are coming soon.
Prior

Thursday November 18, 2021 8:00 AM EST
Jefferies London Healthcare Conference

Monday September 13, 2021 7:00 AM EDT
H.C. Wainwright 23rd Annual Global Investment Conference

SEC Filings

Filing date Description Form Filing Group View
D
Other
View HTML

A preliminary proxy statement providing notification matters to be brought to a vote

PRE 14A
Proxy Filings
View HTML

A preliminary proxy statement providing notification matters to be brought to a vote

PRE 14A
Proxy Filings
View HTML

Investor Contacts

E-mail: IR@nabriva.com

 

Data Provided by Refinitiv. Minimum 15 minutes delayed.